Seattle Genetics submits supplemental BLA for Adcetris in CTCL

Application is based on clinical trial results from the Phase 3 ALCANZA and Phase 2 investigator-sponsored studies in cutaneous T cell lymphoma

Register for free to listen to this article
Listen with Speechify
BOTHELL, Wash.—Seattle Genetics Inc. announced June 21 that it had submitted a supplemental Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) based on data from the Phase 3 ALCANZA trial and two Phase 2 investigator-sponsored trials of Adcetris (brentuximab vedotin) in patients with cutaneous T cell lymphoma (CTCL). Adcetris is currently not approved for the treatment of CTCL.
“The submission of the supplemental BLA requesting label expansion for Adcetris as a treatment in CTCL patients who require systemic therapy is an important milestone. CTCL is an incurable and disfiguring disease in need of new therapeutic options, particularly those that achieve durable responses,” said Dr. Jonathan Drachman, chief medical officer and executive vice president of research and development for Seattle Genetics. “Results from the Phase 3 ALCANZA trial demonstrated that CTCL patients treated with Adcetris had superior outcomes across all primary and secondary endpoints compared to patients in the control arm who were treated with either methotrexate or bexarotene standard of care agents. In addition to the ALCANZA results, data from two investigator-sponsored trials also support Adcetris use in this disease setting. We believe these data are clinically meaningful and support a label expansion for Adcetris in CTCL, which would be the fourth indication for this program.”
In November 2016, based on preliminary analysis of ALCANZA, the FDA granted Adcetris Breakthrough Therapy Designation (BTD) for the treatment of patients with CD30-expressing mycosis fungoides and primary cutaneous anaplastic large cell lymphoma who require systemic therapy and have received one prior systemic therapy. These represent the most common subtypes of CTCL. Based on discussions with the FDA following the BTD, additional data from investigator-sponsored phase 2 trials have been incorporated into the supplemental BLA to support the potential for a broader label in CTCL.
The supplemental BLA is primarily based on positive results from a Phase 3 trial called ALCANZA that were presented at the 58th American Society of Hematology annual meeting in December 2016 and published in The Lancet in June 2017. Results from the ALCANZA trial in 128 CTCL patients requiring systemic therapy included:
  • The trial achieved its primary endpoint with the Adcetris treatment arm demonstrating a highly statistically significant improvement in the rate of objective response lasting at least four months.
  • Key secondary endpoints specified in the protocol, including complete response rate, progression-free survival and reduction in the burden of symptoms during treatment (Skindex-29), were all highly statistically significant in favor of the Adcetris arm.
  • The safety profile associated with Adcetris from the ALCANZA trial was generally consistent with the existing prescribing information. The most common adverse events of any grade include: peripheral neuropathy, nausea, diarrhea, fatigue, vomiting, alopecia, pruritis, pyrexia, decreased appetite and hypertriglyceridemia.
Lymphoma is a general term for a group of cancers that originate in the lymphatic system. There are two major categories of lymphoma: Hodgkin lymphoma and non-Hodgkin lymphoma. Cutaneous lymphomas are a category of non-Hodgkin lymphoma that primarily involve the skin. According to the Cutaneous Lymphoma Foundation, CTCL is the most common type of cutaneous lymphoma and typically presents with red, scaly patches or thickened plaques of skin that often mimic eczema or chronic dermatitis. Progression from limited skin involvement may be accompanied by skin tumor formation, ulceration and exfoliation, complicated by itching and infections. Advanced stages are defined by involvement of lymph nodes, peripheral blood and internal organs.
The standard treatment for systemically pretreated CTCL includes skin-directed therapies, radiation and systemic therapies. The systemic therapies currently approved for treatment have demonstrated 30 to 45 percent objective response rates, with low complete response rates.
Adcetris is being evaluated broadly in more than 70 ongoing clinical trials, including three Phase 3 studies:  the ongoing ECHELON-1 trial in frontline classical Hodgkin lymphoma and the ongoing ECHELON-2 trial in frontline mature T-cell lymphomas, as well as the completed ALCANZA trial in cutaneous T-cell lymphoma, from which data were submitted in the supplemental BLA noted above.
Adcetris is an antibody-drug conjugate (ADC) that consists of an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing Seattle Genetics’ proprietary technology. The ADC employs a linker system that is designed to be stable in the bloodstream but to release MMAE upon internalization into CD30-positive tumor cells.

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

DDN Magazine May 2024

Latest Issue  

• Volume 20 • Issue 3 • May 2024

May 2024

May 2024 Issue